Trial reportFrontiers in veterinary science2026
Evaluating the safety and efficacy of equine peripheral blood-derived mesenchymal stem cells in feline chronic gingivostomatitis.
Trial report in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Feline chronic gingivostomatitis (FCGS) is a painful chronic disease with limited treatment options, especially in severe cases. For this reason, regenerative therapies are being explored as a potential solution. Methods: The current study investigates the safety and efficacy of systemic application of equine peripheral blood-derived mesenchymal stem cells (ePB-MSCs) in 16 cats with feline chronic gingivostomatitis (FCGS). A blinded, randomized, placebo-controlled study was performed in one veterinary practice with daily owner evaluations and veterinary visits on days -7, 0, 21 ± 3, 42 ± 3, and 84 ± 3 (optional: 182 ± 5). Results: In both treatment groups, one adverse event and one serious adverse event were reported, which were not linked to the treatment. Hematology and biochemistry assessments did not result in any remarkable changes. The change in Stomatitis Disease Activity Index Score (SDAI) did not show a significant effect for time ( Discussion: In conclusion, the single intravenous application of ePB-MSCs in cats suffering from FCGS was safe. Based on the current data using the current study design, there was no evidence that the application was more effective than the control. Further studies evaluating the efficacy of equine peripheral blood-derived mesenchymal stem cells in cats suffering from chronic gingivostomatitis with a longer follow-up, different evaluation parameters, and/or adjusted treatment regimen are recommended.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.